Interim safety data show that pregnant women vaccinated with the bivalent prefused subunit RSV vaccine RSVpreF (Abrysvo) had similar safety outcomes to unvaccinated women. The preliminary analysis did not reveal new or unexpected safety signals associated with the vaccine in pregnant women. The incidence of adverse effects and serious adverse events was comparable between the vaccinated and unvaccinated groups. The data also did not show an increased incidence of pregnancy complications or adverse effects in newborns after maternal vaccination. The study followed pregnant women who received the vaccine during pregnancy and compared them to a control population without vaccination. The authors of the article emphasize that these are interim (interim) results and safety monitoring is ongoing. The main finding is that the data to date support a favorable safety profile of this RSV vaccine in pregnancy.